<VariationArchive RecordType="classified" VariationID="1217262" VariationName="NC_000023.10:g.(31697704_31747747)_(31893491_31947712)del" VariationType="Deletion" Accession="VCV001217262" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-11-04" DateCreated="2021-09-08" MostRecentSubmission="2021-09-08">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1207242" VariationID="1217262">
      <GeneList>
        <Gene Symbol="DMD" FullName="dystrophin" GeneID="1756" HGNC_ID="HGNC:2928" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xp21.2-21.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="31119222" stop="33339388" display_start="31119222" display_stop="33339388" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="31137344" stop="33357725" display_start="31137344" display_stop="33357725" Strand="-" />
          </Location>
          <OMIM>300377</OMIM>
          <Haploinsufficiency last_evaluated="2019-11-20" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=DMD">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2019-11-20" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=DMD">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000023.10:g.(31697704_31747747)_(31893491_31947712)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xp21.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" outerStart="31697704" innerStart="31747747" innerStop="31893491" outerStop="31947712" display_start="31697704" display_stop="31947712" variantLength="145745" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.(31697704_31747747)_(31893491_31947712)del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.(31697704_31747747)_(31893491_31947712)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000023.10:g.(31697704_31747747)_(31893491_31947712)del AND Qualitative or quantitative defects of dystrophin" Accession="RCV001582371" Version="1">
        <ClassifiedConditionList TraitSetID="8840">
          <ClassifiedCondition DB="MedGen" ID="C5679787">Qualitative or quantitative defects of dystrophin</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-08-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-08-20" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-09-08" MostRecentSubmission="2021-09-08">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">26911353</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31705731</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="8840" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="9486" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Qualitative or quantitative defects of dystrophin</ElementValue>
                <XRef ID="MONDO:0016147" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2031" />
                <XRef ID="2031" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The dystrophinopathies cover a spectrum of X-linked muscle disease ranging from mild to severe that includes Duchenne muscular dystrophy, Becker muscular dystrophy, and DMD-associated dilated cardiomyopathy (DCM). The mild end of the spectrum includes the phenotypes of asymptomatic increase in serum concentration of creatine phosphokinase (CK) and muscle cramps with myoglobinuria. The severe end of the spectrum includes progressive muscle diseases that are classified as Duchenne/Becker muscular dystrophy when skeletal muscle is primarily affected and as DMD-associated DCM when the heart is primarily affected. Duchenne muscular dystrophy (DMD) usually presents in early childhood with delayed motor milestones including delays in walking independently and standing up from a supine position. Proximal weakness causes a waddling gait and difficulty climbing stairs, running, jumping, and standing up from a squatting position. DMD is rapidly progressive, with affected children being wheelchair dependent by age 12 years. Cardiomyopathy occurs in almost all individuals with DMD after age 18 years. Few survive beyond the third decade, with respiratory complications and progressive cardiomyopathy being common causes of death. Becker muscular dystrophy (BMD) is characterized by later-onset skeletal muscle weakness. With improved diagnostic techniques, it has been recognized that the mild end of the spectrum includes men with onset of symptoms after age 30 years who remain ambulatory even into their 60s. Despite the milder skeletal muscle involvement, heart failure from DCM is a common cause of morbidity and the most common cause of death in BMD. Mean age of death is in the mid-40s. DMD-associated DCM is characterized by left ventricular dilation and congestive heart failure. Females heterozygous for a DMD pathogenic variant are at increased risk for DCM.</Attribute>
                <XRef ID="NBK1119" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301298</ID>
                <ID Source="BookShelf">NBK1119</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/DMD_Pathogenic_Variants.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Pathogenic Variant in Dystrophin (DMD Gene) and elevated creatine kinase muscle isoform (CK-MM), Duchenne and Becker Muscular Dystrophy, 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2020">
                <URL>https://www.acmg.net/PDFLibrary/DMD_CKMM.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated creatine kinase muscle isoform (CKMM), Genetic Neuromuscular Disease, 2020</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/DMD-Elevated-CKMM-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, ELEVATED CREATINEKINASE(CK)-MM , Genetic Neuromuscular Disorders, 2022</CitationText>
              </Citation>
              <XRef ID="207085" DB="Orphanet" />
              <XRef ID="C5679787" DB="MedGen" />
              <XRef ID="MONDO:0016147" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3562432" SubmissionDate="2021-09-01" DateLastUpdated="2021-09-08" DateCreated="2021-09-08">
        <ClinVarSubmissionID localKey="NC_000023.10:g.(31697704_31747747)_(31893491_31947712)del|MedGen:CN043595" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001821327" DateUpdated="2021-09-08" DateCreated="2021-09-08" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-08-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">26911353</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31705731</ID>
          </Citation>
          <Comment>Variant summary: The variant identified by MLPA or other technology involves the deletion of exons 48-52 in the DMD gene. A presumed nomenclature of c.(6912+1_6913-1)_(7660+1_7661-1)del has been designated for the purposes of this classification. Although exact breakpoints of this deletion are not known, it is expected to result in a frameshift in the DMD gene, a known mechanism of disease. The variant was absent in 16120 control chromosomes. c.(6912+1_6913-1)_(7660+1_7661-1)del has been reported in the literature in individuals affected with Dystrophinopathies (e.g. Okubo_2016, Ling_2020). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="DMD" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.(31697704_31747747)_(31893491_31947712)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN043595" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10303367</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3562432" TraitType="Disease" MappingType="XRef" MappingValue="CN043595" MappingRef="MedGen">
        <MedGen CUI="C5679787" Name="Qualitative or quantitative defects of dystrophin" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

